Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Bone Marrow
  • Gangliosides
  • Immunoglobulin G
  • Immunotherapy
  • Neoplasm, Residual
  • Neuroblastoma

abstract

  • BM MRD after two cycles of immunotherapy was confirmed as an early response marker and a consistent independent predictor of survival.

publication date

  • March 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4334779

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.57.6777

PubMed ID

  • 25559819

Additional Document Info

start page

  • 755

end page

  • 63

volume

  • 33

number

  • 7